Barclays said it believes that a recent pullback tied to Middle East tensions has improved the risk-reward profile for Align Technologies . The bank upgraded the orthodontics company to overweight from equal weight. Analyst Glen Santangelo's $200 price target implies that shares could climb 18% from Monday's close. ALGN 1Y mountain ALGN 1Y chart Santangelo pointed out that shares had touched $197 in early February following the release of Align's strong fourth-quarter results and fiscal 2026 year guidance. But the stock has been swept up in a broader market pullback. "The Middle East conflict has triggered a 15% pullback from the recent Feb high, improving the risk/reward. Admittedly, if the conflict drags on, our call may prove to be premature," the analyst wrote. "However, trading at 10x EBITDA, we believe ALGN is well positioned to benefit post-conflict." Santangelo pointed to Align's fourth-quarter results, which suggest renewed momentum in business. Even more impressive, he wrote, was the balance across each of Align's market segments and geographies. The analyst added that website traffic to both Align's homepage and My Invisalign page suggest that last quarter's positive trend has persisted this quarter as well. "We are encouraged by the continued strength of the data, particularly as consensus has revenues modeled down 2.4% sequentially from 4Q to 1Q," he added. Santangelo said Align's revenue exposure to the Middle East falls within the single-digit territory and that the company has a manufacturing plant in Israel. "As of Friday, the facility remains operational and unaffected by the ongoing conflict. While we do not believe there has been any material impact to the company's financial outlook up to this point, we appreciate the fluidity of the situation," he wrote.
